Loading...

Arix Bioscience plc

ARIX.L•LSE
Healthcare
Biotechnology
£142.00
£-1.50(-1.05%)

Arix Bioscience plc (ARIX.L) Stock Overview

Explore Arix Bioscience plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.5/100

Key Financials

Market Cap183.7M
P/E Ratio-6.82
EPS (TTM)$0.11
ROE-0.11%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$164.93

ARIX.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Arix Bioscience plc (ARIX.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $164.93.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.82 and a market capitalization of 183.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ARIX.LStats details for ARIX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ARIX.LAnalyst Recommendations details for ARIX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.

CEO

Tom Davidson

Employees

9

Headquarters

Duke Street House, London

Founded

2017

Frequently Asked Questions

;